Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23960623 | 0.83 | ALDH1A1 (0.58) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL10042103 | 0.74 | USP2 (0.63) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL23960622 | 0.73 | CYP1A2 (0.36) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL25495427 | 0.67 | CYP1A2 (0.56) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL25495438 | 0.67 | CYP1A2 (0.56) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL27726 | 0.63 | CYP1A2 (0.81) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL2338208 | 0.63 | CYP1A2 (0.81) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL7416439 | 0.63 | CYP1A2 (0.81) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL6377387 | 0.63 | CYP1A2 (0.81) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3866042 | 0.63 | CYP1A2 (0.81) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150922-A1 | Fluorinated Derivatives of Gabapentin and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150922-A1 | Fluorinated Derivatives of Gabapentin and Methods of Use Thereof | GABRE, GABBR1, GABRB3 | CYP1A2 1530/4885USP2 4550/4885ALDH1A1 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.